Their favorable safety profile, together with evidence of potent anti-myeloma activity, low cytotoxicity against healthy cells (lung, PBMCs), with a basal expression of NKG2D ligands, and absence of GvHD in preclinical models, positions NKG2D as a compelling complement to lineage-specific targets such as BCMA. The gene discussed is KLRK1; the disease is plasma cell myeloma.